NCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
Clinical Trials
14 trialsNCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT06682572 2025-12-17
RAMP201J
Verastem, Inc.
Phase 2 Active not recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT04625270 2025-01-29
RAMP 201
Verastem, Inc.
Phase 2 Active not recruiting
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT04620330 2024-01-12
RAMP202
Verastem, Inc.
Phase 2 Completed
NCT02943317 2019-04-30
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Verastem, Inc.
Phase 1 Terminated
NCT01778803 2017-05-17
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Verastem, Inc.
Phase 1 Completed
NCT01951690 2017-04-13
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Verastem, Inc.
Phase 2 Completed
NCT01943292 2017-03-09
Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
Verastem, Inc.
Phase 1 Completed
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated
NCT02372227 2017-01-30
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
Phase 1 Terminated
NCT00787033 2017-01-25
B0761001
Verastem, Inc.
Phase 1 Completed